Nephrolitiasis and Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A Meta-analysis Of Randomized Controlled Trials

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) decreased serum uric acid in type 2 diabetes. Hyperuricemia is associated with an increased risk of nephrolithiasis. The present meta-analysis, performed on trials with duration ≥52 weeks in comparison with placebo or active comparators, suggests no effects of SGLT-2i on the risk of nephrolithiasis.

Source: Diabetes Research and Clinical Practice - August 7, 2019 Category: Endocrinology Authors: Claudia Cosentino, Ilaria Dicembrini, Besmir Nreu, Edoardo Mannucci, Matteo Monami Tags: Brief Report Source Type: research